Gilead Sciences, Inc.

1) Strategic Overview and Leadership Insights - Gilead reported a strong Q2 2026, with base business sales increasing 10% YoY, marking the best second-quarter growth in three years. - The company is focusing on diversifying its portfolio within virology and expanding into oncology and inflammation. - Key therapeutic areas driving growth include HIV, oncology (Trodelvy), and liver disease (Livdelzi). - Gilead is preparing for multiple product launches, including BIC/LEN in HIV and anito-cel in oncology, expected later in 2026.

2) Financial and Segment Results - Total product sales, excluding Veklury, reached $7.6 billion, up 10% YoY and 12% sequentially. - HIV sales were $5.7 billion, up 12% YoY, driven by Biktarvy, Yeztugo, and Descovy. - Trodelvy sales increased 26% YoY to $457 million, while Livdelzi sales more than doubled to $167 million. - The company raised its full-year HIV sales growth guidance to 9%-10% from 8%.

3) Challenges and Headwinds - The HIV treatment market experienced a slowdown due to changes in the Affordable Care Act, impacting patient insurance coverage. - Cell therapy sales declined 14% YoY to $417 million, reflecting competitive pressures. - Veklury sales are expected to decline to approximately $300 million, down from previous estimates of $600 million, due to fewer COVID-19-related hospitalizations.

4) Operational and Product Plans - Gilead is advancing its HIV pipeline with several new treatment options, including a once-daily oral treatment combining bictegravir and lenacapavir, and a once-weekly regimen expected to launch in 2027. - The company is also focusing on enhancing the persistency of Yeztugo through new support programs for patients. - In oncology, Trodelvy's recent approvals in first-line metastatic triple-negative breast cancer are expected to expand its market reach significantly.

5) Guidance and Outlook - Gilead updated its full-year guidance, expecting base business sales growth of 6%-7% and total product sales between $30.1 billion and $30.4 billion. - Non-GAAP diluted EPS is projected to be between negative $0.65 and negative $0.30, with a significant impact from acquired IPR&D expenses. - The company remains focused on integrating recent acquisitions and does not anticipate pursuing additional large-scale M&A in the near term.

Bottom line: Gilead's strong Q2 performance, driven by robust growth in its HIV and oncology segments, positions the company well for continued success. With multiple product launches on the horizon and a commitment to diversifying its portfolio, Gilead is poised for long-term growth, despite facing some near-term challenges in the HIV treatment market.